Aaron L Ellenbogen DO
Movement Disorder
Neurologist in Farmington, Michigan and is affiliated with multiple hospitals in the area, including Beaumont Hospital-Farmington Hills and Beaumont Hospital-Troy
Join to View Full Profile
28595 Orchard Lake RdSte 200Farmington Hills, MI 48334
Phone+1 248-553-0010
Fax+1 248-553-5957
Dr. Ellenbogen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Michigan State University College of Osteopathic MedicineClass of 1998
Certifications & Licensure
MI State License 1999 - 2025
AOA Board of Neurology and Psychiatry Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PrimeSUITE EHR, Greenway Health, LLC, 2013
Clinical Trials
- Study of SPARC1103 in Subjects With Spasticity Start of enrollment: 2014 Apr 21
- Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease Start of enrollment: 2014 Jun 01
- A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease Start of enrollment: 2016 Nov 30
Publications & Presentations
PubMed
- Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinA.Aaron Ellenbogen, Robert A Hauser, Atul T Patel, Peter McAllister, Todd M Gross
Toxins. 2025-03-12 - Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study.Aaron L Ellenbogen, Werner Poewe, Alberto J Espay, Tanya Simuni, Tanya Gurevich
Parkinsonism & Related Disorders. 2025-03-01 - CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial.Nicola L Brice, Mark Carlton, David H Margolin, Martin Bexon, Kim L Matthews
Eclinicalmedicine. 2024-11-01
Journal Articles
- Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinica...Jankovic J1, Goodman I2, Safirstein B3, Marmon TK4, Schenk DB4, Koller M4, Zago W4, Ness DK4, Griffith SG5, Grundman M6,7, Soto J4, Ostrowitzki S8, Boess FG9, Martin-F..., JAMA Neurology, 10/2018
Press Mentions
Two Early Symptoms of Parkinson’s Disease Were Discovered. They Are Not ClearApril 4th, 2022
Titan to Start Phase 1/2 Study of Subdermal Implant to Deliver Requip to Parkinson’s PatientsSeptember 1st, 2017- Alcanza’s Quest Research Institute Advocates Awareness and Education During Parkinson’s Disease Awareness Month; Provides Updates on Recent Parkinson’s Disease ResearchApril 27th, 2024
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
